A1203AFB-95EC-4EAF-9290-BDB74432403C
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.180026281208935
- age_years
- 43
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.406
- NOTCH_SIGNALING+0.393
- INTERFERON_ALPHA_RESPONSE+0.345
- MITOTIC_SPINDLE+0.342
- PROTEIN_SECRETION+0.324
- WNT_BETA_CATENIN_SIGNALING+0.302
- ANDROGEN_RESPONSE+0.250
- HEDGEHOG_SIGNALING+0.230
- DNA_REPAIR+0.222
- MYC_TARGETS_V2+0.219
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.398
- KRAS_SIGNALING_DN-0.262
- SPERMATOGENESIS-0.255
- ALLOGRAFT_REJECTION-0.232
- TNFA_SIGNALING_VIA_NFKB-0.207
- IL6_JAK_STAT3_SIGNALING-0.198
- INFLAMMATORY_RESPONSE-0.191
- ANGIOGENESIS-0.181
- MYOGENESIS-0.160
- COAGULATION-0.149
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 221384A6-059C-4731-9BD0-68EC9CA5651D | — | — | 0.887 |
| 2 | 7CE18C10-61E6-45FA-B9AF-408CD673C0C9 | — | — | 0.860 |
| 3 | 21D48ADE-2798-4380-999A-9485A70E7D2A | — | — | 0.853 |
| 4 | 8441B707-EC45-4A38-8B83-99B8D83CCF8B | — | — | 0.847 |
| 5 | 0093DCB6-A7C8-4841-8383-0671A71DDA71 | — | — | 0.845 |
| 6 | C6ACBA34-164B-419D-9C2B-ED2DC3C68FDD | — | — | 0.842 |
| 7 | 53426017-24F2-4348-BEE1-05E80B6A0E6B | — | — | 0.839 |
| 8 | SRR934799 | — | — | 0.835 |
| 9 | 111625A4-390B-4D8C-BF80-020062CE9D89 | — | — | 0.828 |
| 10 | 4992152D-1D3D-4156-9D80-1B6810AAE78F | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.406 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.393 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.345 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.342 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.324 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.302 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.222 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.219 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.159 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.145 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.141 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.136 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.136 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.121 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.116 | Idelalisib | — uncovered |